Atossa Therapeutics, Inc. (ATOS)
Market Cap | 101.62M |
Revenue (ttm) | n/a |
Net Income (ttm) | -24.30M |
Shares Out | 126.62M |
EPS (ttm) | -0.19 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 94,963 |
Open | 0.820 |
Previous Close | 0.801 |
Day's Range | 0.787 - 0.820 |
52-Week Range | 0.500 - 1.620 |
Beta | 1.13 |
Analysts | Buy |
Price Target | 5.10 (+535.51%) |
Earnings Date | Feb 27, 2023 |
About ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-1... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ATOS stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 535.51% from the latest price.
News

The 3 Best Biotech Stocks Under $1 to Buy for January
While biotech may be the next big thing, making money through it isn't easy. Indeed, investing in biotech stocks is often more of an art than a science.

Atossa Therapeutics Issues Letter to Shareholders
SEATTLE, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet...

Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations
SEATTLE, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical ne...

Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on recent...

Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy
SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (...

Atos returns to sales growth in Q3, beats market expectations
France's Atos said on Wednesday its sales returned to growth in the third quarter, beating expectations as the loss-making IT consulting firm strives to regain markets' trust by carrying out a costly ...

Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.
Oversaw FDA approval of CAR-T/CAR-NK cell therapy, ADCs, and small molecule/targeted therapies for hematology-oncology diseases Oversaw FDA approval of CAR-T/CAR-NK cell therapy, ADCs, and small molec...

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer
Atossa to begin Phase 2 Study of (Z)-endoxifen in 4th Quarter Atossa to begin Phase 2 Study of (Z)-endoxifen in 4th Quarter

Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference
SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet m...

Registration Now Open for Tribe Public's Webinar Event "The Important Role For Inhalation Therapy In Oncology" Featuring The Management Team From Atossa Therapeutics on August 25, 2022
Meet with Atossa's CEO & Founder, Dr. Steven Quay, M.D., Ph.D. & Kyle Guse, GC & CFO Meet with Atossa's CEO & Founder, Dr. Steven Quay, M.D., Ph.D. & Kyle Guse, GC & CFO

Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board
The Company Re-Appoints Drs. Mak Jawadekar, Per Hall, and Carl Novina The Company Re-Appoints Drs. Mak Jawadekar, Per Hall, and Carl Novina

Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infe...

Dosing Completed in Part C of Atossa's Phase 1/2a Study of AT-H201 in Healthy Volunteers
Atossa Plans to Initiate a New Development Path in Patients with Compromised Lung-Function Resulting from Cancer Treatment Atossa Plans to Initiate a New Development Path in Patients with Compromised ...

Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations
SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of signific...

Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference
SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significa...

Atossa Therapeutics to Present at the Q2 Investor Summit Conference
SEATTLE, April 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet m...

Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201
NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE

Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference
SEATTLE, March 23, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious dise...

Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious dise...

Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update
SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious dise...

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022
SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet me...

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201
Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection Pulmonary Disease Nebulized Formulation Being Devel...

Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden
SEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet med...

Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut Pasteur
SEATTLE, Dec. 16, 2021 /PRNewswire/ -- Physician-Scientist Steven Quay, MD, PhD has published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in Se...

Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration
Input Received on Pathway for Proprietary Z-Endoxifen to Treat Breast Cancer in Neoadjuvant Setting Input Received on Pathway for Proprietary Z-Endoxifen to Treat Breast Cancer in Neoadjuvant Setting